Many thanks from all of us on the thread for your time and effort Mr President Sir. You make this the best informed thread on the platform. |
 Well, here we finally are (drumroll please someone). I had to pick 10 from the rough 20 names which we either know from OXB or could reasonably guess at from what has been found by searching around over the years. At the interims we will be told how many partners we currently have and of course there are actually many more where for whatever reason either OXB or the customer didn't want the publicity.
I've left some very good prospects out of this list (why Serum want a huge bioreactor for 10 years to name just one), but when it comes to the number 1 spot then there can be only one (as I seem to remember an Italian nobleman with a Scottish accent saying in a film once).
Novartis. The pioneers and first to market with a CAR-T treatment. A treatment for which OXB's LentiVector process is essential and part of the regulatory approval.
Over 7,000 patients treated so far with Kymriah. A large portion of those being kids with a very nasty blood cancer who had run out of other chances - and if that doesn't tug at the old heartstrings about what our company plays an essential part in then nothing will.
Difficult to work out exactly how much our Kymriah work earns us, but somewhere between £15m and £20m of our sales last year seems reasonable.
Remember of course that whilst earnings are for the life of the drug, and that the market share can change (both ways), the next generation Kymriah (again using our LentiVector) which gets grown on directly in the patient (rather than a bioreactor) is currently in clinical trials as T-Charge.
So these are the T-Charge trials as YTB323 which I've always understood to be the better mousetrap to Kymriah (the Mk2 if you prefer).
Anybody with doubts - National Library of Medicine says "YTB323, a novel autologous CD19-directed CAR T-cell therapy expressing the same validated CAR as tisagenlecleucel, is manufactured using a next-generation platform in <2 days."
Tisagenlecleucel of course is the licenced drug name for the Kymriah marketing brand name.
Aside from that Novartis are also trialling T-Charge in BCMA (not CD19 like Kymriah) with the code name PHE885. At this point I'm guessing at our involvement and those trials are further ahead.
So whether PHE885 uses the OXB LentiVector like YTB323 is a secret, but if you look at this EMA pdf for PHE885
All the familiar words are there, it's just a different target.
And that concludes the 10 working day interims results countdown:-
10 - Sardocor (Cardiac gene therapy) post 8579
9 - Cargo Therapeutics (Bicistronic and tricistronic CARs) post 8596
8 - Oxford University labs (Lassa Fever vaccine) post 8601
7 - Boehringer Ingelheim (Cystic Fibrosis) post 8607
6 - Immatics (T-cell-redirecting cancer immunotherapies) post 8610
5 - Beam Theraputics (allogeneic CAR-T for leukemia and lymphoma) post 8621
4 - Kyverna Therapeutics (non-cancer CAR-T for autoimmune diseases) post 8630
3 - GeoVax (universal covid and monkeypox vaccine) post 8650
2 - BMS (CAR-T and TCR-T) post 8663
1 - Novartis (Approved commercial CAR-T partner / T-Charge coming) post 8668 |
A blue end to the day with some volume would be a nice sign. |
Improving CAR-T Cell Efficacy via New Manufacturing Process |
Afternoon Plutonian & thanks for your thoughts as always.
I appreciate this is out of character for me, but I actually tried to keep that one short so cut out what would have been too much to read.
I hadn't spotted the drug name in the first link, but I did see the date which is why I mention the second link as relevant as I thought we would have a piece of that.
But (I know, but, but, but) ages ago I found a few EMA links which I posted on here at the time, because I couldn't decide if BMS were applying for an alternative vector - or just an alternative vector supplier.
At the time I was obviously hoping that they were going to use LentiVector, but I appreciate that would involve confirmatory trials which we haven't seen. Later I heard Frank say multiple times that OXB are happy to manufacture (or improve) any 3rd party vector outside of what we offer ourselves. That jogged the earlier memory for me and I wondered if we might be helping / ready to help BMS with their previously (quite public) bottlenecks.
EMA made me think Europe / European manufacturer / OXB and then I remembered Stuart's specific mention of hoping to hear something from BMS soon in a number of webcasts (remembering that "soon" with a regulator can be quite a long time).
So I was vague I know, which is a bit of a cop out, but unfortunately BMS are tight lipped and I wanted to write something for our number 2 spot.
Back when OXB used to pay Edison to knock out notes, Edison had these words against BMS "Juno (BMS) collaboration on undisclosed CAR-T/TCR-T therapies; assumptions are for JCAR018 in pALL and r/r NHL".
Whenever I see something like that on a broker note, I always wonder how they could guess something like that unless they had received a massive hint?
Another broker (I saw the note at the time) thought our initial 4 were these
JCAR018 – targeting CD22, in Phase 1 development for paediatric ALL, non-
Hodgkin lymphoma)
JCAR023 – targeting CD171, In Phase 1 development for paediatric
neuroblastoma
JCAR020 – targeting MUC16, in Phase I development for ovarian cancer
JCAR024 – targeting ROR1, in Phase I development for non-small cell lung cancer,
triple-negative breast cancer.
I'm of the same opinion re guessing those.
I've tried to translate those into what succeeded / exists as a current BMS pipeline drug and I couldn't come up with anything concrete.
I'm confident we have something with BMS, and of course we have customers who are partnered with BMS. BMS also interchangeably refer to themselves as BMS or the "division of" name (like Celgene) which doesn't help either. |
Harry, yes we have many irons in the BMS fire.
You mention JCAR017 as the Juno lead product, but this is already marketed as Breyanzi (lisocabtagene maraleucel, liso-cel) and pre-dates any OXB involvement. Are you suggesting they have changed the vector to OXB LentiVector? It is not on my list of probable OXB products. |
There's plainly waning interest in the 2 week interims results countdown, but as it's only 2 working days left now then I'll just press on:-
10 - Sardocor (Cardiac gene therapy) post 8579
9 - Cargo Therapeutics (Bicistronic and tricistronic CARs) post 8596
8 - Oxford University labs (Lassa Fever vaccine) post 8601
7 - Boehringer Ingelheim (Cystic Fibrosis) post 8607
6 - Immatics (T-cell-redirecting cancer immunotherapies) post 8610
5 - Beam Theraputics (allogeneic CAR-T for leukemia and lymphoma) post 8621
4 - Kyverna Therapeutics (non-cancer CAR-T for autoimmune diseases) post 8630
3 - GeoVax (universal covid and monkeypox vaccine) post 8650
2 - BMS (CAR-T and TCR-T) post 8663
1 - ???
As mentioned 2 working days to go, and I'm sure some of you will have guessed where I'm going to end up at tomorrow by now, but today - 6th / 7th biggest pharmaceutical company in the world by prescription drug revenues - Bristol Myers Squibb.
18th March 2020 we sign a deal with Juno for them to use our LentiVector on their CAR-T / TCR-T drug pipeline, see but at this point Juno has just become a BMS company.
2022 they were pleased enough to come back for a deal on more targets
The big Juno trial is this one (320 patients) CAR-T in Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL).
The 6 relevant others are in this list here
So, Follicular Lymphoma, Multiple Myeloma, Multiple Sclerosis, Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy and Systemic Sclerosis.
BMS are a huge company and it's difficult to track what they are up to (they don't have to spell it out for the benefit of supplier company small shareholders), but with these multiple Juno trials (2 very late stage) then the odds / statistics are in favour of getting at least one result. As we know from our happy experience with Novartis, we only need a partner to get one good drug approved and it's a payday for us for the lifetime of the drug. |
They have already told us the story though Ygor, haven't they?
Previous guidance was reaffirmed only last month, so you know what the headline figures are going to be and still on track for profitability next year.
OXB's first half is always worse than the second. This has been explained previously as because their suites come offline / out of service for deep cleaning early in the year (as opposed to the routine continual cleaning) and I assume that's still the same.
But if Lucy presents in the same way Stuart did (I can't imagine why she wouldn't) then you will get the H1 figures, then post period to either the end of August or the interims with cash and orders, etc. You will also get a revised forecast of the FY figures where 85% or so is already booked in (so that will be very close to what we actually see in April).
More cash has been burnt than anticipated - but for good reasons. They have now almost certainly decided to renew the lease on Yarnton (which was up this year and supposed to be temporary until OxBox could accommodate all under one roof). That will have cost money which they had probably previously earmarked as a saving and of course that can only really have happened if OxBox is too busy to take the Novartis work from Yarnton - so actually a good reason to be spending money.
Yes the cash will be less now, because of that and the new staff they have been constantly recruiting, but when the invoices start getting paid next year for the extra work this allows them to do then all will be forgiven.
Many people have noted this besides me, but smallcap is a bit under the radar. People are aware you are there and they might even know why OXB ended up there post covid, but they aren't really paying attention. Best example I can give of that would be the MF writer (recent article) who had OXB as his top pick but with a really shaky description of what OXB is / does.
Currently the interest isn't there and you can see that in action here with the PI's on this thread. Not much new interest is there? (And in some cases not much old interest). Hopefully Frank's policy of saving up news for the big push will pay dividends this time.
For me, then I think if he can simply name the new commercial CAR-T deal (signalled in March) and state what it's worth to us, then that alone should break the dam. |
It will be the numbers that dominate the debate on Monday. We are still in a cash-burn situation so however many good opportunities we have unless we can get them to pay we're just potential buzzard bait. Rights issue? |
Well if there are any market moving surprises in store for us on Monday the market doesnt seem to be expecting them. |
Yes we are:
Yes, Oxford Biomedica is indeed involved in the production of lentiviral vectors for KYV-101. Kyverna Therapeutics has a formal agreement with Oxford Biomedica to utilize their LentiVector® platform for KYV-101, which is a CAR T-cell therapy targeting autoimmune diseases like lupus nephritis. Multiple sources confirm that Oxford Biomedica is responsible for supplying the lentiviral vectors that are integral to the development of KYV-101 [oai_citation:2,Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform | Kyverna Therapeutics](hxxps://kyvernatx.com/press-releases/kyverna-oxford-biomedica-sign-license-and-supply-agreement-for-lentivector-platform/) [oai_citation:1,Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector Platform - MarketScreener](hxxps://www.marketscreener.com/quote/stock/OXFORD-BIOMEDICA-PLC-43524070/news/Kyverna-Therapeutics-and-Oxford-Biomedica-Sign-License-and-Supply-Agreement-for-LentiVector-Platform-44895795/). |
Day number 4 on my countdown pb. They are on a PR offensive. If any of their lines eventually works out then happy days. |
Apologies, it's a bad linkHTTps://ir.kyvernatx.com/news-releases/news-release-details/kyverna-therapeutics-presents-patient-data-reinforcing-potential |
Not sure if we're involved?HTTps://ir.kyvernatx.com/news-releases/news-release-details/kyverna-therapeutics-presents-patient-data-reinforcing-potentialpHTTps://kyvernatx.com/press-releases/kyverna-oxford-biomedica-sign-license-and-supply-agreement-for-lentivector-platform/ |
OXB...a much better company than Oxford Biomedica ever was! |
What a waste of energy and money.
It makes no difference at all.
We need the phonejacker call asking to speak to the see-yeeeeyo of oxber
My Pa used to ask me why I wrote WALOB in my journal when attending pointless meetings. |
Market doesn't like companies that put their efforts into fripperies such as name/logo/etc. changing. |
After that damp squib, 3 working days to go and my selection for bronze position is GeoVax.
Some of you will remember, but back in April Phil was awarded the thread "floppy ears and wet nose" badge (with oakleaves), which is only presented rarely for sniffing out something important which everybody else has missed.
ABL Europe (then Oxford Biomedica Europe for less than a year and presumably now just OXB squiggle) are the MVA (Modified Vaccinia Ankara vector) manufacturer for GeoVax. Basically GEO-CM04S1 for universal covid and GEO-MVA for smallpox / monkeypox as far as we are concerned.
Important to point out here that the MVA doesn't belong to OXB (nee ABL Europe) in exactly the same way that the AV in Oxford University / Astra's covid vaccine didn't belong to OXB either - but there was an awful lot of money to be made in simply manufacturing it.
GeoVax recent H1 results 6th August
Selected quotes:-
"Vaccine Manufacturing Process Development
Produced first lot of GEO-CM04S1 with a commercial manufacturing platform, a critical step toward implementation of a validated chicken embryonic fibroblast (CEF) based production system for the company’s MVA-based vaccines. This milestone marks the successful completion of the transfer and scale-up of manufacturing from the research-focused Center for Biomedicine & Genetics at City of Hope to Oxford Biomedica, the Company’s cGMP (current Good Manufacturing Procedures) manufacturing partner."
(and)
"Second Quarter Business Achievements
GEO-CM04S1
Received BARDA Project NextGen award through the Rapid Response Partnership Vehicle (RRPV) to advance development of GEO-CM04S1, GeoVax’s dual-antigen next-generation COVID-19 vaccine, in a Phase 2b clinical trial. The direct award to GeoVax of approximately $24.3 million, which may increase to as much as $45 million, will fund the manufacturing of clinical materials and support for the Phase 2b clinical trial, including regulatory activities.
Under the agreement, GeoVax will sponsor a 10,000-participant, randomized, Phase 2b double-blinded study to compare the efficacy, safety, and immunogenicity of GEO-CM04S1 with a U.S. Food and Drug Administration (FDA) approved mRNA COVID-19 vaccine. Preparations for the study are underway, and execution of the study will be funded by BARDA under its Clinical Studies Network.
The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS).
Funding for this award is provided under Project NextGen, a $5 billion initiative by HHS to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19 than the first generation COVID vaccines and medicines."
Me again (I've finished quoting) and I realise I'm pointing out the obvious here (sorry), but in the first copied passage we learn that scale up and transfer to OXB was complete and in the second passage the amount of government money they have already been awarded to fund clinical trial material and trials. In other words that's a given and old ABL Europe / new OXB squiggle will very soon be earning a lot of money from that - possibly eventually topping what we paid for the whole company on just this contract alone.
I'd strongly recommend listening to the boss of GeoVax as he is a very good speaker. This is the latest presentation only days ago at the HCW conference you can type anything in the registration boxes (I did) well worth 20 mins of your time to hear how the US government are currently throwing money at this plus much more.
GeoVax have 3 priority programmes two of which are MVA of interest to us (universal covid and the disease formally known as monkey pox).
Both are Smallpox base jabs modified for Monkeypox with the universal covid jab being a second add-on i.e. if you opt for the covid jab you get mpox / smallpox for free.
Usual caveats here that I am an OXB squiggle armband wearer and not a scientist / medic, but it strikes me that there is potential for an awful lot of money on the table here for the manufacturer of a universal covid vaccine which also protects you from monkeypox - hence place number 3 on the countdown. |
I have to say Dom, that I'm less than thrilled.
This will cost a small fortune in changing everything which has our name / logo on it and a lot of paper stuff (admittedly that's a lot less than it used to be these days) will just go straight into the skip. They've doubtless also paid someone a small fortune to come up with the new font / squiggle.
The slight upside is it's an indication that Frank has a "big show" planned for Monday.
The downside for me (and I know that you will remember this one well) is that once British Petroleum's global ambitions reached America, they were basically forced to drop the British link as there was no way the Americans were going to allow that name after the quasi merger with a US giant.
That of course lasted until the Deepwater Horizon disaster when you couldn't stop the greatest president who ever lived from referring to BP as British Petroleum something like 15 times in one press conference.
I hope there's not an American merger coming - but I think Novo would put their foot down if it was. |
Well that should fix the undervaluing..... just what we have all been waiting for. |
Oovarvo - (vic reeves) |
Excelcia!? |
At least it's not Consignia... |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
